Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC study

Oaknin, A.Iglesias, M.Alarcon, J. D.Villacampa Javierre, G.Gaba Garcia, L.Santaballa, A.Manso, L. M.Romero, I.Barretina Ginesta, M. P.Churruca, C.Garcia, Y.Sanchez, A. B.Marquina, G.Pardo, B.Redondo, A.Rubio, M. J.Gonzalez Martin, A.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/25336enRandomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC studyconference outputopen access10.1016/j.annonc.2020.08.10191569-8041http://www.annalsofoncology.org/article/S0923753420410154/pdf573469101168